X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cell biology (3) 3
humans (3) 3
index medicus (3) 3
acute myeloid-leukemia (2) 2
azacitidine (2) 2
cancer (2) 2
health aspects (2) 2
hemic and lymphatic diseases (2) 2
molecular targeted therapy (2) 2
myelodysplastic syndromes (2) 2
older patients (2) 2
oncology (2) 2
research paper (2) 2
5-azacytidine (1) 1
5q deletion (1) 1
acute myeloid leukemia (1) 1
affinity (1) 1
aml (1) 1
animals (1) 1
antimetabolites, antineoplastic - administration & dosage (1) 1
antimetabolites, antineoplastic - pharmacology (1) 1
antineoplastic agents - chemistry (1) 1
antineoplastic agents - pharmacology (1) 1
azacitidine - administration & dosage (1) 1
azacitidine - analogs & derivatives (1) 1
azacitidine - pharmacology (1) 1
azanucleoside (1) 1
basigin - drug effects (1) 1
basigin - genetics (1) 1
basigin - metabolism (1) 1
biochemistry & molecular biology (1) 1
biological effects (1) 1
biomolecules (1) 1
blood diseases (1) 1
bruton's tyrosine kinase (1) 1
cancer therapies (1) 1
cancer-therapy (1) 1
carcinogenesis (1) 1
care and treatment (1) 1
cell cycle proteins - drug effects (1) 1
cell cycle proteins - genetics (1) 1
cell cycle proteins - metabolism (1) 1
cell line, tumor (1) 1
cell survival (1) 1
cellular differentiation (1) 1
cellular proteins (1) 1
cereblon (1) 1
chemical proteomics (1) 1
chromatin (1) 1
chronic myelomonocytic leukemia (1) 1
classification (1) 1
clinical trials (1) 1
clinical trials as topic (1) 1
combination (1) 1
comprehensive analysis (1) 1
conventional care regimens (1) 1
crenolanib (1) 1
cytokines - metabolism (1) 1
data processing (1) 1
data quality (1) 1
decision making (1) 1
decitabine (1) 1
deregulation (1) 1
dexamethasone combination (1) 1
dk/atira/pure/subjectarea/asjc/2700/2730 (1) 1
dna methylation - drug effects (1) 1
dna methyltransferase (1) 1
drug development (1) 1
drug discovery (1) 1
drug discovery - methods (1) 1
drug resistance, neoplasm (1) 1
drug therapy (1) 1
drugs (1) 1
e3 ubiquitin ligase (1) 1
elderly-patients (1) 1
embryonic structures (1) 1
embryos (1) 1
epidermal growth factor (1) 1
epidermal growth factor receptors (1) 1
epigenesis, genetic - drug effects (1) 1
epigenetic regulation (1) 1
expression profiles (1) 1
family (1) 1
flt3-itd (1) 1
fms-like tyrosine kinase 3 - antagonists & inhibitors (1) 1
genetic aspects (1) 1
genetics & heredity (1) 1
hematologic neoplasms - drug therapy (1) 1
hematologic neoplasms - genetics (1) 1
hematopoietic stem cells (1) 1
hematopoietic stem-cells (1) 1
hma (1) 1
imatinib (1) 1
immunity (1) 1
immunologic factors - pharmacology (1) 1
immunosuppressive agents - pharmacology (1) 1
inhibitor (1) 1
inhibitor selectivity (1) 1
inhibitors (1) 1
innovations (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 12/2017, Volume 358, Issue 6367, p. eaan4368
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug... 
REFINEMENT | PROTEIN | CHEMICAL PROTEOMICS | INHIBITOR SELECTIVITY | DATA QUALITY | QUANTIFICATION | MULTIDISCIPLINARY SCIENCES | INTEGRATIVE GENOMICS VIEWER | SALT-INDUCIBLE KINASES | CANCER | COMPREHENSIVE ANALYSIS | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Lung Neoplasms - drug therapy | Lung Neoplasms - enzymology | Cytokines - metabolism | Humans | Drug Discovery - methods | Antineoplastic Agents - chemistry | Molecular Targeted Therapy | Xenograft Model Antitumor Assays | Leukemia, Myeloid, Acute - enzymology | Protein Kinase Inhibitors - chemistry | Animals | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Proteomics - methods | Salts | Target recognition | Lung cancer | Selectivity | Drug development | Cancer therapies | Signal transduction | Biomolecules | Protein-tyrosine kinase | Tyrosine | Medical research | Imatinib | Decision making | Medical treatment | Mass spectroscopy | Tumor necrosis factor-α | Embryos | Bruton's tyrosine kinase | Mode of action | Side effects | Inhibitors | Interleukin 10 | Affinity | Drug discovery | Mass spectrometry | Acute myeloid leukemia | Drugs | Deregulation | Leukemia | Interleukin | Medical services | Clinical trials | Leucine | Kinases | Biological effects | Epidermal growth factor | Salt-inducible kinase | Xenografts | Cell survival | Epidermal growth factor receptors | Research & development--R&D | Therapeutic applications | Myeloid leukemia | Markers | Data processing | Lead compounds | Leucine zipper proteins | Signaling | Proteomics | Cancer | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2016, Volume 22, Issue 7, pp. 735 - 743
Immunomodulatory drugs (IMiDs), such as thalidomide and its derivatives lenalidomide and pomalidomide, are key treatment modalities for hematologic... 
MEDICINE, RESEARCH & EXPERIMENTAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | THALIDOMIDE | CEREBLON | MULTIPLE-MYELOMA CELLS | CANCER-THERAPY | CELL BIOLOGY | 5Q DELETION | LENALIDOMIDE | DEXAMETHASONE COMBINATION | MYELODYSPLASTIC SYNDROMES | T-CELLS | E3 UBIQUITIN LIGASE | Cell Cycle Proteins - drug effects | Oncogene Proteins - genetics | Peptide Hydrolases - genetics | Humans | Peptide Hydrolases - drug effects | Thalidomide - pharmacology | RNA, Messenger - metabolism | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Basigin - genetics | Basigin - drug effects | Cell Cycle Proteins - genetics | Immunosuppressive Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Peptide Hydrolases - metabolism | RNA, Messenger - drug effects | Myelodysplastic Syndromes - metabolism | Teratogenesis - genetics | Cell Cycle Proteins - metabolism | Oncogene Proteins - metabolism | Multiple Myeloma - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Oncogene Proteins - drug effects | Signal Transduction - drug effects | Basigin - metabolism | Myelodysplastic Syndromes - genetics | Immunologic Factors - pharmacology | Multiple Myeloma - genetics | Teratogenesis - drug effects | Cellular proteins | Immunity | Carcinogenesis | Health aspects | Patient outcomes | Risk factors | Proteins | Drug therapy | Multiple myeloma | Tumors | Index Medicus
Journal Article
Blood advances, ISSN 2473-9529, 12/2018, Volume 2, Issue 23, pp. 3447 - 3461
Mesenchymal stromal cells (MSCs) are crucial components of the bone marrow (BM) microenvironment essential for regulating self-renewal, survival, and... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.